HC Wainwright Rates Ocular Therapeutix (OCUL) buy

HC Wainwright has reaffirmed its buy rating on Ocular Therapeutix, Inc., maintaining a $25 price target that sits well above where shares currently change hands, a 147.16% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 12:01 PM EDT · Updated Jun 24, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Ocular Therapeutix, Inc. ($OCUL) "buy" with a $25 price target on June 18, 2026.

Since the rating, $OCUL is up 3.5% after 1 week, down 7.6% after 1 month and down 27.1% to date (from the $9.43 close on Jun 18, 2026).

OCUL Ocular Therapeutix, Inc.

$6.87 -41.88% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright analyst Yi Chen reiterated a buy rating on Ocular Therapeutix, Inc. (NasdaqGM: OCUL) on June 18, 2026, keeping a price target of $25.00.
HC Wainwright's $25 price target implies 147.16% upside from Ocular Therapeutix, Inc.'s ($OCUL) current $10.12 share price.
The biotech stock trades near $10.12, giving the company a market value of about $2.19 billion while moving close to its 50-day average of $9.86.
A broader group of 11 covering firms supports a strong buy consensus with a mean target price of $27.09 ahead of earnings on November 4, 2026.

Get $OCUL trade alerts by text

We text you when insiders, Congress or big funds trade $OCUL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Ocular Therapeutix, Inc. alert may contain errors. Disclosures

HC Wainwright Reaffirms Outlook on Ocular Therapeutix Stock

HC Wainwright & Co. analyst Yi Chen kept a buy rating on Ocular Therapeutix, Inc. (NasdaqGM: OCUL) on June 18, 2026, alongside a $25.00 price target. This target points to a sizable gap between the firm's goal and where the equity actually trades, focusing attention on how much upside the covering analyst sees for the biopharmaceutical developer.

12-month forecast

$OCUL price target

Ocular Therapeutix, Inc. daily closes and this analyst's $25 target. Not advice.

Where Ocular Therapeutix Stock Trades Today

Shares of Ocular Therapeutix changed hands around $10.12 on Thursday, leaving the company with a market capitalization near $2.19 billion. The equity has spent the past year moving between a low of $6.23 and a high of $16.44. Current pricing places the shares just above the 50-day moving average of $9.86 and the 200-day moving average of $9.88, reflecting a steady baseline as investors weigh the clinical progress of its hydrogel-based therapies.

Analysts Set New Price Targets

Wall Street firms continue to maintain an optimistic stance on the company's treatment pipeline. On October 12, 2026, UBS initiated coverage with a buy rating and a $14.00 price target. Earlier on October 2, 2026, Chardan Capital maintained a buy rating with a $23.00 target, matching its stance from September 16, 2026. Needham also reiterated a buy rating with an $18.00 target on September 29, 2026, while HC Wainwright held its $25.00 target on September 16, 2026. Chardan Capital previously kept a buy rating with a $23.00 target on August 4, 2026, after raising it from $21.00 on June 25, 2026. Across 11 analysts tracking the firm, the stock carries a strong buy recommendation key and a mean price target of $27.09, with individual projections running from a low of $18.00 up to a high of $34.00.

What Ocular Therapeutix Does

Based in Bedford, Massachusetts, Ocular Therapeutix develops treatments for retinal diseases and other eye conditions using its proprietary bioresorbable hydrogel formulation technology. The firm markets DEXTENZA to treat post-surgical ocular pain and inflammation, while advancing clinical candidates like AXPAXLI for wet age-related macular degeneration and OTX-TIC for glaucoma.

Looking Ahead to Upcoming Milestones

Investors are keeping track of upcoming financial disclosures, with the company scheduled to report its next set of earnings results on November 4, 2026. These updates will offer more color on spending for clinical trials and commercial progress for its approved inserts without altering the backward-looking nature of recent analyst updates.